Polymorphism in The DNA Repair Gene XRCC3 and Therapeutic Outcomes in Patients with AML

Among the lesions induced by chemotherapeutic drugs, DNA doublestrand breaks (DSB) are considered the most serious ones that can result in cell death, if it is not properly repaired. Homologous recombination (HR) pathway is the main system for DSB repair and XRCC3 has a key role in this pathway. Protein activity can be affected by the XRCC3 polymorphism. Thus, in this study, the association between XRCC3 Thr241Met polymorphism and therapeutic outcomes was investigated. The study population consisted of 67 adult patients with de novo AML(range: 1565 years). XRCC3 Thr241Met polymorphism was determined by PCRRFLP technique. Clinical data were collected from patients’ medical records. There were no significant association between XRCC3 genotype and therapeutic outcome (P=0.764). We found no considerable correlation between XRCC3 genotype and age (P=0.255), gender (P=0.239), AMLsubtype (P=0.961) as well asWBC count (P=0.629). There are only a few studies conducted on the relationship between therapeutic outcomes and XRCC3 Thr241Met polymorphism in AML patients and the reported findings are controversial. Accordingly, further studies will be required to clarify the effect of XRCC3 Thr241Met polymorphism on therapeutic outcome.